Open-Label Tiagabine Monotherapy for Major Depressive Disorder With Anxiety
J Clin Psychiatry 2006;67:66-71
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
acid (GABA) plays a key role in the
pathophysiology and treatment of depression and anxiety.
Tiagabine, a selective GABA reuptake inhibitor
(SGRI) that enhances normal GABA tone, was
evaluated for its efficacy and safety in the treatment of
depression comorbid with significant anxiety.
Method: In this 8-week, single-center,
open-label study, adults with DSM-IV-diagnosed
major depressive disorder and significant anxiety
(i.e., "anxious depression") received tiagabine
monotherapy, initiated at 4 mg/day and titrated for
optimum response as tolerated to a maximum dose of 20 mg/day. Symptoms, function, and
adverse events were assessed at regular intervals.
Patients were entered from April 2002 to February 2003.
Results: Nineteen patients entered the
study and 15 met criteria for intent-to-treat analyses.
Of those, 6 (40%) discontinued treatment and 9 (60%) completed the 8-week protocol.
Tiagabine significantly improved depression, as shown by
a reduction in mean ± SD Hamilton Rating Scale
for Depression scores from baseline (31.9 ± 6.1)
to endpoint (17.0 ± 12.4; p = .002). Categorical
response rate was 47% (N = 7). Tiagabine also significantly improved anxiety (Hamilton
Rating Scale for Anxiety baseline score of 22.7 ± 4.9
vs. endpoint score of 12.5 ± 8.8; p=.002). The mean±SD final daily dose was 12.8 ± 5.8 mg.
The most commonly reported adverse events were dizziness, headache, and gastrointestinal
Conclusion: These results suggest the
potential of the SGRI tiagabine in the treatment of
depression with anxiety. Large, placebo-controlled trials are needed.